Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation
1 news sources are covering this Technology story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation" is generating significant coverage in the Technology category, with 1 articles from 1 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Tech Funding News. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 33d ago.
Quick answers
Why is "Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valua" trending?
Because 1 independent news sources published 1 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (1)
Topics
Related trends
Colossal, Game-Changing Dragon's Dogma 2 Patch 3.2 Out Now on PS5
12 news sources are covering this Technology story right now — PULSE is tracking how fast it spreads.
Argenx to Buy Forte Biosciences for $2.2 Billion
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Wooly Mammoth startup Colossal seeking at least $20B valuation
De-extinction startup Colossal Biosciences is reportedly pursuing a new funding round with a target valuation between $20 billion and $30 billion.